Department of Gynecologic Oncology and Reproductive Medicine and the Department of Health Services Research, the University of Texas MD Anderson Cancer Center, and the Department of Epidemiology, Human Genetics and Environmental Sciences, School of Public Health, the University of Texas Health Science Center at Houston, Houston, Texas; Unidad Ginecología Oncológica, Grupo de Investigación GIGA, Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo (CTIC), and Clínica Universitaria Colombia, Bogotá, Colombia; and the Department of Obstetrics, Gynecology, and Reproductive Sciences, School of Medicine, Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.
Obstet Gynecol. 2024 Jun 1;143(6):824-834. doi: 10.1097/AOG.0000000000005570. Epub 2024 Apr 5.
To assess the effect of geographic factors on fertility-sparing treatment or assisted reproductive technology (ART) utilization among women with gynecologic or breast cancers.
We conducted a cohort study of reproductive-aged patients (18-45 years) with early-stage cervical, endometrial, or ovarian cancer or stage I-III breast cancer diagnosed between January 2000 and December 2015 using linked data from the California Cancer Registry, the California Office of Statewide Health Planning and Development, and the Society for Assisted Reproductive Technology. Generalized linear mixed models were used to evaluate associations between distance from fertility and gynecologic oncology clinics, as well as California Healthy Places Index score (a Census-level composite community health score), and ART or fertility-sparing treatment receipt.
We identified 7,612 women with gynecologic cancer and 35,992 women with breast cancer. Among all patients, 257 (0.6%) underwent ART. Among patients with gynecologic cancer, 1,676 (22.0%) underwent fertility-sparing treatment. Stratified by quartiles, residents who lived at increasing distances from gynecologic oncology or fertility clinics had decreased odds of undergoing fertility-sparing treatment (gynecologic oncology clinics: Q2, odds ratio [OR] 0.76, 95% CI, 0.63-0.93, P =.007; Q4, OR 0.72, 95% CI, 0.56-0.94, P =.016) (fertility clinics: Q3, OR 0.79, 95% CI, 0.65-0.97, P =.025; Q4, OR 0.67, 95% CI, 0.52-0.88, P =.004), whereas this relationship was not observed among women who resided within other quartiles (gynecologic oncology clinics: Q3, OR 0.81 95% CI, 0.65-1.01, P =.07; fertility clinics: Q2, OR 0.87 95% CI, 0.73-1.05, P =.15). Individuals who lived in communities with the highest (51 st -100 th percentile) California Healthy Places Index scores had greater odds of undergoing fertility-sparing treatment (OR 1.29, 95% CI, 1.06-1.57, P =.01; OR 1.66, 95% CI, 1.35-2.04, P =.001, respectively). The relationship between California Healthy Places Index scores and ART was even more pronounced (Q2 OR 1.9, 95% CI, 0.99-3.64, P =.05; Q3 OR 2.86, 95% CI, 1.54-5.33, P <.001; Q4 OR 3.41, 95% CI, 1.83-6.35, P <.001).
Geographic disparities affect fertility-sparing treatment and ART rates among women with gynecologic or breast cancer. By acknowledging geographic factors, health care systems can ensure equitable access to fertility-preservation services.
评估地理因素对患有妇科或乳腺癌的女性选择保留生育能力的治疗或辅助生殖技术(ART)的影响。
我们使用加利福尼亚癌症登记处、加利福尼亚州全州卫生规划和发展办公室以及辅助生殖技术协会的链接数据,对 2000 年 1 月至 2015 年 12 月期间诊断为早期宫颈癌、子宫内膜癌或卵巢癌或 I-III 期乳腺癌的育龄期患者(18-45 岁)进行了队列研究。广义线性混合模型用于评估距离生育和妇科肿瘤学诊所的距离,以及加利福尼亚健康场所指数评分(一个基于普查的综合社区健康评分)与接受 ART 或保留生育能力治疗之间的关系。
我们确定了 7612 名患有妇科癌症的女性和 35992 名患有乳腺癌的女性。所有患者中,有 257 人(0.6%)接受了 ART。在患有妇科癌症的患者中,有 1676 人(22.0%)接受了保留生育能力的治疗。按四分位数分层,居住在距离妇科肿瘤学或生育诊所越来越远的地方的患者,接受保留生育能力治疗的可能性降低(妇科肿瘤学诊所:Q2,比值比[OR]0.76,95%CI,0.63-0.93,P =.007;Q4,OR 0.72,95%CI,0.56-0.94,P =.016)(生育诊所:Q3,OR 0.79,95%CI,0.65-0.97,P =.025;Q4,OR 0.67,95%CI,0.52-0.88,P =.004),而居住在其他四分位数的女性则没有这种关系(妇科肿瘤学诊所:Q3,OR 0.81,95%CI,0.65-1.01,P =.07;生育诊所:Q2,OR 0.87,95%CI,0.73-1.05,P =.15)。居住在加利福尼亚健康场所指数得分最高(第 51 百分位至第 100 百分位)的社区的个体,接受保留生育能力治疗的可能性更大(OR 1.29,95%CI,1.06-1.57,P =.01;OR 1.66,95%CI,1.35-2.04,P =.001)。加利福尼亚健康场所指数得分与 ART 之间的关系更为明显(Q2 OR 1.9,95%CI,0.99-3.64,P =.05;Q3 OR 2.86,95%CI,1.54-5.33,P <.001;Q4 OR 3.41,95%CI,1.83-6.35,P <.001)。
地理差异影响了患有妇科或乳腺癌的女性选择保留生育能力的治疗和 ART 率。通过认识到地理因素,医疗保健系统可以确保公平获得生育保护服务。